Amyloidosis - 24 Studies Found

Status	Study
Not yet recruiting	Study Name: Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis Condition: Amyloidosis Date: 2017-01-03 Interventions: Other: 18-F Florbetapir PET/MR scan 18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
Recruiting	Study Name: Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis Condition: Amyloidosis Date: 2016-03-14 Interventions: Other: blood collection Other: bone marrow
Completed	Study Name: Recurrent AA Amyloidosis After Renal Transplantation Condition: AA Amyloidosis Date: 2016-03-04
Terminated	Study Name: Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis Condition: Amyloidosis Date: 2015-09-09 Interventions: Drug: Idelalisib Idelalisib daily until unacceptable toxicity or disease progression.
Not yet recruiting	Study Name: A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Condition: Amyloidosis Date: 2015-08-27 Interventions: Drug: Carfilzomib Lyophilized
Suspended	Study Name: Trial of HDM/SCT Versus HDM + Bortezomib/SCT in AL Amyloidosis Condition: AL Amyloidosis Date: 2015-03-09 Interventions: Drug: Bortezomib
Completed	Study Name: Allo SCT in Amyloidosis Non-interventional Study Condition: AL Amyloidosis Date: 2014-10-02
Recruiting	Study Name: Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis Condition: Amyloidosis Date: 2014-09-15 Interventions: Drug: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 The antibody binds to the pathologic material
Completed	Study Name: Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis Condition: Amyloidosis Date: 2013-11-15 Interventions: Drug: Bortezomib Other Name: V
Active, not recruiting	Study Name: Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Condition: Primary Amyloidosis Date: 2012-10-11 Interventions: Drug: NEOD001 Monoclonal antibody administered by intravenous infusion every 28 days.